17:57 , Nov 9, 2018 |  BC Week In Review  |  Company News

NextCure, Lilly partner to find new immuno-oncology targets

PD-1 pioneer Lieping Chen's NextCure Inc. (Beltsville, Md.) partnered with Eli Lilly and Co. (NYSE:LLY) to use the biotech's FIND-IO platform to discover immuno-oncology targets. FIND-IO identifies new targets on immune-suppressive macrophages, dendritic cells and...
21:44 , Nov 5, 2018 |  BC Extra  |  Company News

NextCure, Lilly partner to find new immuno-oncology targets

PD-1 pioneer Lieping Chen's NextCure Inc. (Beltsville, Md.) partnered with Eli Lilly and Co. (NYSE:LLY) to use the biotech's FIND-IO platform to discover immuno-oncology targets. FIND-IO identifies new targets on immune-suppressive macrophages, dendritic cells and...
18:36 , Jan 11, 2018 |  BC Innovations  |  Emerging Company Profile

Next, after T cells

PD-1 pioneer Lieping Chen is solving some of the unanswered questions from that breakthrough with his new company, NextCure Inc. The idea is to use myeloid cell factors to boost the effectiveness of other T...
08:00 , Jan 25, 2016 |  BioCentury  |  Strategy

Preclinical hunting ground

With a new dedicated preclinical investment initiative, Pfizer Inc. is hoping to more systematically evaluate and invest in the large number of opportunities that fall between its academic translational research collaborations and its venture arm....
01:32 , Jan 7, 2016 |  BC Extra  |  Financial News

Ex-Amplimmune execs reunite for NextCure

Immuno-oncology newco NextCure Inc. (New Haven, Conn.) raised $67 million in a series A round. The company's management team includes former executives from Amplimmune Inc. , which AstraZeneca plc (LSE:AZN; NYSE:AZN) acquired in 2013 (see...
07:00 , Jun 22, 2015 |  BioCentury  |  Strategy

Getting to goal

Bringing in a new CMO with a proven track record in cancer looks like AstraZeneca plc's best shot at recovering from a string of setbacks and hitting the lofty approval and revenue targets it set...
07:00 , May 12, 2014 |  BioCentury  |  Strategy

Build up to break up

Pfizer Inc. continues to give signals that the grand plan is to break itself up, and the reality looks like it absolutely needs AstraZeneca plc 's assets to make it work. Pfizer already has internally...
08:00 , Jan 13, 2014 |  BioCentury  |  Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
08:00 , Nov 25, 2013 |  BioCentury  |  Strategy

AstraZeneca BD 3.0

AstraZeneca plc 's latest iteration of business development is pushing the center of gravity even further toward R&D. After a 2012 restructuring put search and evaluation for early stage assets into the hands of researchers,...
07:00 , Oct 21, 2013 |  BioCentury  |  Strategy

MedImmune's warheads

AstraZeneca plc 's latest pair of deals - the acquisition of Spirogen Ltd. and a partnership with ADC Therapeutics S.a.r.l. - gives the pharma's MedImmune LLC biologics unit all the tools it needs for antibody-drug...